Latest News
Quidel Announces Preliminary Revenue for Fourth Quarter 2020; Will Present Virtually at 39th Annual J.P. Morgan Healthcare Conference
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects revenues in the fourth quarter of 2020 to be in the range of $808 mill...
Quidel In The News
San Diego Business Journal - Quidel Delivers Record Profits
FOX Business - Quidel CEO: New strain of coronavirus won’t affect performance of our tests
NBC News Los Angeles - New coronavirus test gives results in minutes, not days
MSN - Quidel's game-changing test key to reopening economy?
Wall Street Journal - FDA to grant emergency use status for first coronavirus antigen test by Quidel
New York Times - FDA approves first antigen test for detecting coronavirus
Careers
Are you a determined, optimistic, team player? Quidel is looking for talented innovators who want to be part of revolutionizing medical diagnostics.
Support
To place orders, get assistance with shipments, pricing or contract administration view our Customer Support page.
Visit our Technical Support page to get help with product specifications, supporting docs or general support issues.
For Package Inserts and supporting docs visit our Document Search Tool
NEW: Visit ConnectMe.quidel.com for help connecting your Quidel Instruments to the cloud, including the Virena surveillance system.
Register at MyQuidel.com to download and install the latest Software Updates, Assay and testing capabilities for your Quidel Instruments.